DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0148449 A1 Kuliopulos Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0148449 A1 Kuliopulos Et Al US 2003O1484.49A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0148449 A1 Kuliopulos et al. (43) Pub. Date: Aug. 7, 2003 (54) G PROTEIN COUPLED RECEPTOR Related U.S. Application Data AGONSTS AND ANTAGONSTS AND METHODS OF ACTIVATING AND (63) Continuation-in-part of application No. 09/841,091, INHIBITING G PROTEIN COUPLED filed on Apr. 23, 2001. RECEPTORS USING THE SAME (60) Provisional application No. 60/198.993, filed on Apr. (76) Inventors: Athan Kuliopulos, Winchester, MA 21, 2000. (US); Lidija Covic, Somerville, MA (US) Publication Classification Correspondence Address: (51) Int. Cl." .......................... A61K 38/17; C12P 21/02; Ingrid A. Beattie, Ph.D., J.D. C12N 5/06; CO7K 14/705; Mintz, Levin, Cohn, Ferris, A61K 31/20 Glovsky and Popeo, P.C. (52) U.S. Cl. ..................... 435/69.1; 435/320.1; 435/325; One Financial Center 530/350; 514/12; 514/558 Boston, MA 02111 (US) (57) ABSTRACT (21) Appl. No.: 10/251,703 The invention relates generally to G protein coupled recep tors and in particular to agonists and antagonists of G protein (22) Filed: Sep. 20, 2002 receptors and methods of using the Same. Patent Application Publication US 2003/0148449 A1 Patent Application Publication US 2003/0148449 A1 Z 0 Ca2+ (ARBITARY UNITS) Patent Application Publication Aug. 7, 2003. Sheet 3 of 28 US 2003/0148449 A1 Plpol-19 Plpol-19 w SFLRN SFLLRN SFLLRN ! P p Fig. 1C Plpol-13 Pi3-9 Y - - Plpol-19Q Pipal-19E y - Pir 19 Plpol-2 Y - - ----- SFL RN Y Plpol-7 (D 0 Y 4. - t PALMECACD Y H- m - --- F C CD as 100 200 AGGREGATION S Fig. 1D Patent Application Publication Aug. 7, 2003 Sheet 4 of 28 US 2003/0148449 A1 PLATELETS 100 OY s Fluor-i3 Z t; Fluor-Pal-i3 s s O it Tim In 10 02 O3 LOG FLUORESCENCE FIBROBLASTS OO Y A. s Fluor-i} Z 5 Fluor-Pa-i3 s Y O I - I T O 02 OG FLUORESCENCE Y - / Fig. 1E Patent Application Publication Aug. 7, 2003 Sheet 5 of 28 US 2003/0148449 A1 PAR SEQ ID NO: 1 PAR2 SEQ ID NO: 7 PAR4 SEQ ID NO: 9 Plpol-19 SEQ ID NO: 1 Plpal-l3 SEQ LD NO: 2 P. pal-7 SEQ ID NO:3 P. pal-l2 SEQ ID NO: 4 Pl pal-l9Q SEQ ID NO: 5 Pl pal-l9E SEQ ID NO: 6 P2 pol-2 SEQ LD NO: 7 P2 pol-2F SEQ ID NO:8 C - PALMITATE Fig. 2A PAR-ROt 100 s 80 - - A - Plpol-13 5 -O- Plpol-12 O ... O ... Plpol-7 () 60 O Y OL 9 40 20 08 06 lo ?pal-peptidel (M) Fig. 2B Patent Application Publication Aug. 7, 2003. Sheet 6 of 28 US 2003/0148449 A1 100 -- A - Plpol-19 PAR-ROt -A-. Plpol-19Q ---O--- Plpol-19E 8-O- MASTOPARAN - X: Plpol-19/ 60 Rot (alone 4O 2O O - titmi t-tim t t t im it trim t t tim 08 10° o peptide) (M) Fig. 2C PAR2-COS/ CS - O €d 27 OU P2pal-2F 5 2 O O Y OL Ol f C P2pal-2) mini i tTg it its tim 0-0 08 106 0 (pal-peptidel (M) Fig. 2D Patent Application Publication Aug. 7, 2003. Sheet 7 of 28 US 2003/0148449 A1 E. Pipal-l3 O EXTRACELULAR AGONS Pipal-19 O EXTRACEULAR Patent Application Publication Aug. 7, 2003. Sheet 8 of 28 US 2003/0148449 A1 P2pal-2F 6 P2pal-2 m EXTRACELULAR G5 AGONS S2 3 4. 3 O 32 C OO 5 O P Pol-19 (M) Fig. 3A Patent Application Publication Aug. 7, 2003. Sheet 9 of 28 US 2003/0148449 A1 OO 5 O O -4 O -2 100 10 -8 THROMBIN) (M) Fig. 3B O WT OO S309P O A377 5 O O-7 O -5 SFL RN) (M) Fig. 3C Patent Application Publication Aug. 7, 2003. Sheet 10 of 28 US 2003/0148449 A1 vs. SFLLRN SFLLRN 2 D a. J.- SFRN E5. A AYPGKF 5. 2 Plpol-2 y AYPGKF - O A 5 2OOS P4pal-l5 PAR4 PAR Fig. 4A SFLLRN AYPGKF 8Y +Plpol-12 +P4paf-l5 < : 200s 5. | (-) (-) 20 Fig. 4B Patent Application Publication Aug. 7, 2003 Sheet 11 of 28 US 2003/0148449 A1 5 O OO 0-8 07 06 O-5 pal-peptide) (M) Fig. 4C 5 O O O O 8 07 06 05 04 pol-peptide) (M) Fig. 4D Patent Application Publication Aug. 7, 2003. Sheet 12 of 28 US 2003/0148449 A1 ?NI??C?C?GTSNIVÈLENBd-TTHO Etz'6|- NWTOTTBOVNIXEA ONW79||| Patent Application Publication Aug. 7, 2003 Sheet 13 of 28 US 2003/0148449 A1 FIUOr-Pol-i3 FIUOr-i3 OO -- - - - - -- C-NTACT CELLS SC-SONICATED CELS 8O (v) Z z 60 5 in SONICATE, 2ND PRONAS t -LL 40 s SONICATE, 2ND PRONASE t 2O - ass PRONASE - - - - -- - - - - - -- C SC C SC EXP if 2 3 5 6 7 8 Patent Application Publication Aug. 7, 2003. Sheet 14 of 28 US 2003/0148449 A1 I:ON(IIÒGIS z:ONCIIÒGIS Iz:0N(IIÒGIS ZZ:ON(IIÒ?S £z:ONCIIOAS ?Z:ON(IIÒGIS 6°:ON(IIÒ?S yTerraepae----------------------------------------------------------------------------SNOECIWIKISS!!TWRI §TASISTESybrae,SSEJAHI--------------------------------------------------------------------------§SSXAX{ d'OOT£| §TA?IYDI,IN:SSNSHIYIN:HSSSÐISTÖHTIGTDRidd'!).IX?IXDOCISCIEXXÔSSLLSåDI---(EDTOESODI?S™ELECHI??ZTETI JITHASYD!------------------------------------------------------------------------------S^{N(AVISSSTICH yAay?ay?:SA?RTHA(GIS------------------------------------------------------------SCÉDEIG?S??M?TI:I !T!!!!!!----------------------------------------------------------------------------------3)S(TILH Patent Application Publication Aug. 7, 2003 Sheet 15 of 28 US 2003/0148449 A1 MAX ACTIVATION t t t t it r t t t Tim t t t t its 08 O7 06 O Fig. 6B (AGONIST) (M) MAX AINATION CCKB 3OONM 8 CCK-8 Ol A. C Z 4 O Plpol-19 C) 9 a A. O l Pipal-l3 O - - Tri- rtm tit- SS; 08 O7 06 05 Fig. 6C AGONIST) (M) Patent Application Publication Aug. 7, 2003 Sheet 16 of 28 US 2003/0148449 A1 - MAX ACTIVATION SS AGONIST) (M) Fig. 6D Patent Application Publication Aug. 7, 2003. Sheet 17 of 28 US 2003/0148449 A1 r OO 8O 5. O-MSH ais se 5 40 MC4pal-l4 g 2O O 0-0 08 06 O' AGONIST) (M) Fig. 7 Patent Application Publication Aug. 7, 2003 Sheet 18 of 28 US 2003/0148449 A1 LBS-1 INTERFERENCE OF INTRAMOLECULAR PARACTIVATION THROMBINACTIVATION OF PARI LBS- INTERMOLECULAR 1 LGAND LBS-2 LBS-2 c s - LBS-PE INTERMOLECULAR u- LIGAND LBS-2 c LBS-2 sir s GDP Fig. 8B Patent Application Publication Aug. 7, 2003. Sheet 19 of 28 US 2003/0148449 A1 CC o-c-, o O O) s O O O ll- 2 ors - CD f < C) f CS. eP s itzr O n- C2 \ > CD g - G E3 9/ - l Patent Application Publication Aug. 7, 2003 Sheet 20 of 28 US 2003/0148449 A1 3 nMT SFLRN No a t 2 BS 330 () 200' 400 600 800 O 200 A00 600 TIME (SEC) TIME (SEC) Fig. 9C Fig. 9D (O- LBS C 4. O LBS-PE 2 O -- - O 40 80 2O (PEPTIDE) (uM) Fig. 9E Patent Application Publication Aug. 7, 2003 Sheet 21 of 28 US 2003/0148449 A1 FIG. OA Patent Application Publication Aug. 7, 2003 Sheet 22 of 28 US 2003/0148449 A1 Patent Application Publication Aug. 7, 2003 Sheet 24 of 28 US 2003/0148449 A1 FIG. 2 P<0.002 - PCO.001 3. b >600 - IV-de?ivery 1 500 100 Cld s S 400 2 Fluor-i3 C) s E 300- -- C Fluor-Pal-i3 O 50 d)0. O o 200 g s i roo O O d H 100 (5. C. r. Y O l Lil 0 (n=17) (n=16) (n=16) 10 10? c\ ^ Log fluorescence d ex ove de 1200 50 - S.8 100000 P<0.003 S S 800 Oup wd : 600 2 3 2s w s 400 D E 9 200 O y O - so o a' epilAYPGKF - H s ses ov ob. P4pal-10) - - 0.3 1 3 micromoles/L Patent Application Publication Aug. 7, 2003. Sheet 25 of 28 US 2003/0148449 A1 Figure 13. Chare 1 Channel 2 Charine Cannel 4 Channe Charlet 2 Channel 3 Charle 4 300 nMY12pal-24 3 MSFLLRN O. in 1oo- O----- : - - - - - - 100 : s : : O. : 300 nM Y12pa-18. ...go 10----- H -i- - - . .so : ; ; ; 20. r: . so 20 . ; . - - - m r - - - - - -]. +10 MY12pal-24 7. 3 MSFLLRN . : apyrase - - - - W - 8 +3,MY12pal-2440 cri +1 uM Y12pal-2 3MSFLLRN" - - - - - - -- . lo 100.-- : . -- 200 alo CO 80 oroo 20 140 2.00 a.oO 6:00 8:00 100 12: 4:00 & 8 ' ' -- time (minsee) irre (Tinsec) Y12pal-18 Pal-YVRTRGVGKVPRKKVNVF-NH2 SEQ ID NO:33 Y12pal-24 Pal-KELYRSYVRTRGVGKVPRKKVNVF-NH2 SEQ ID NO:34 Patent Application Publication Aug. 7, 2003. Sheet 26 of 28 US 2003/0148449 A1 Figure 14. A. B GLP-1R1 nM GLP-1 GLP-1R vs. 1M pepducin vs. 10 Mi pepducin 500 12000 s s 400 S W GS 8000 Sl2 300 Sl2 as 200 is 4000: CU 100 s SS O O SS m s Q m CSY C s C s G1pa-15 Pal-ANLMSKTDIKCRLAF-NH2 SEQ ID NO:35 G1pa-23 Pal-SIWSKLKANLMSKTDIKCRLAF-NH2 SEQ LD NO:36 Patent Application Publication Aug. 7, 2003 Sheet 27 of 28 US 2003/0148449 A1 Fidure 15. 140 120 60 40 20 Patent Application Publication Aug. 7, 2003 Sheet 28 of 28 US 2003/0148449 A1 Figure 16. trypsin) (M) US 2003/0148449 A1 Aug. 7, 2003 G PROTEIN COUPLED RECEPTORAGONSTS SUMMARY OF THE INVENTION AND ANTAGONSTS AND METHODS OF ACTIVATING AND INHIBITING G PROTEIN 0008.
Load more

Recommended publications
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Recent Advances in Drug Discovery of GPCR Allosteric Modulators
    Recent Advances in Drug Discovery of GPCR Allosteric Modulators ADDEX Pharma S.A., Head of Core Chemistry Chemin Des Aulx 12, 1228 Plan-les-Ouates, Geneva, Switzerland Jean-Philippe Rocher, PhD results in a number of differentiating factors. In fact, most Introduction allosteric modulators have little or no effect on receptor function until the active site is bound by an orthosteric The importance of the allosteric regulation of cellular ligand. Allosteric modulators therefore have multiple functions has been known for decades and even the word potential advantages compared to small molecule and “allosterome,” which describes the endogenous alloste- biologic orthosteric drugs. In particular, they offer new ric regulator molecules of a cell, has been proposed 1. chemistry possibilities allowing access to well known tar- Although best described as modulators of enzymes, gets that have been considered intractable to historical advances in molecular biology and robotic HTS technolo- small molecule approaches. For example, allosteric mod- gies recently allowed the discovery of small molecule allo- ulators may soon be developed for targets which hereto- steric modulators of various biological systems, including fore have been only successfully targeted with proteins GPCR and non-GPCR targets. Today, allosteric modula- and peptides. In other words, allosteric drugs with all the tors appear to be an emerging class of orally available advantages of small molecules － brain penetration, eas- therapeutic agents that can offer a competitive advantage ier manufacturing, distribution and oral administration over classical “orthosteric” drugs. This potential stems - may soon be viewed as the best life cycle management from their ability to offer greater selectivity and differ- strategy for protein therapeutics 2.
    [Show full text]
  • Insights Into Nuclear G-Protein-Coupled Receptors As Therapeutic Targets in Non-Communicable Diseases
    pharmaceuticals Review Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases Salomé Gonçalves-Monteiro 1,2, Rita Ribeiro-Oliveira 1,2, Maria Sofia Vieira-Rocha 1,2, Martin Vojtek 1,2 , Joana B. Sousa 1,2,* and Carmen Diniz 1,2,* 1 Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; [email protected] (S.G.-M.); [email protected] (R.R.-O.); [email protected] (M.S.V.-R.); [email protected] (M.V.) 2 LAQV/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal * Correspondence: [email protected] (J.B.S.); [email protected] (C.D.) Abstract: G-protein-coupled receptors (GPCRs) comprise a large protein superfamily divided into six classes, rhodopsin-like (A), secretin receptor family (B), metabotropic glutamate (C), fungal mating pheromone receptors (D), cyclic AMP receptors (E) and frizzled (F). Until recently, GPCRs signaling was thought to emanate exclusively from the plasma membrane as a response to extracellular stimuli but several studies have challenged this view demonstrating that GPCRs can be present in intracellular localizations, including in the nuclei. A renewed interest in GPCR receptors’ superfamily emerged and intensive research occurred over recent decades, particularly regarding class A GPCRs, but some class B and C have also been explored. Nuclear GPCRs proved to be functional and capable of triggering identical and/or distinct signaling pathways associated with their counterparts on the cell surface bringing new insights into the relevance of nuclear GPCRs and highlighting the Citation: Gonçalves-Monteiro, S.; nucleus as an autonomous signaling organelle (triggered by GPCRs).
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Biased Signaling of G Protein Coupled Receptors (Gpcrs): Molecular Determinants of GPCR/Transducer Selectivity and Therapeutic Potential
    Pharmacology & Therapeutics 200 (2019) 148–178 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential Mohammad Seyedabadi a,b, Mohammad Hossein Ghahremani c, Paul R. Albert d,⁎ a Department of Pharmacology, School of Medicine, Bushehr University of Medical Sciences, Iran b Education Development Center, Bushehr University of Medical Sciences, Iran c Department of Toxicology–Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Iran d Ottawa Hospital Research Institute, Neuroscience, University of Ottawa, Canada article info abstract Available online 8 May 2019 G protein coupled receptors (GPCRs) convey signals across membranes via interaction with G proteins. Origi- nally, an individual GPCR was thought to signal through one G protein family, comprising cognate G proteins Keywords: that mediate canonical receptor signaling. However, several deviations from canonical signaling pathways for GPCR GPCRs have been described. It is now clear that GPCRs can engage with multiple G proteins and the line between Gprotein cognate and non-cognate signaling is increasingly blurred. Furthermore, GPCRs couple to non-G protein trans- β-arrestin ducers, including β-arrestins or other scaffold proteins, to initiate additional signaling cascades. Selectivity Biased Signaling Receptor/transducer selectivity is dictated by agonist-induced receptor conformations as well as by collateral fac- Therapeutic Potential tors. In particular, ligands stabilize distinct receptor conformations to preferentially activate certain pathways, designated ‘biased signaling’. In this regard, receptor sequence alignment and mutagenesis have helped to iden- tify key receptor domains for receptor/transducer specificity.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • Cell Penetrating Peptides, Novel Vectors for Gene Therapy
    pharmaceutics Review Cell Penetrating Peptides, Novel Vectors for Gene Therapy Rebecca E. Taylor 1 and Maliha Zahid 2,* 1 Mechanical Engineering, Biomedical Engineering and Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA; [email protected] 2 Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15201, USA * Correspondence: [email protected]; Tel.: +1-412-692-8893; Fax: +1-412-692-6184 Received: 5 February 2020; Accepted: 1 March 2020; Published: 3 March 2020 Abstract: Cell penetrating peptides (CPPs), also known as protein transduction domains (PTDs), first identified ~25 years ago, are small, 6–30 amino acid long, synthetic, or naturally occurring peptides, able to carry variety of cargoes across the cellular membranes in an intact, functional form. Since their initial description and characterization, the field of cell penetrating peptides as vectors has exploded. The cargoes they can deliver range from other small peptides, full-length proteins, nucleic acids including RNA and DNA, liposomes, nanoparticles, and viral particles as well as radioisotopes and other fluorescent probes for imaging purposes. In this review, we will focus briefly on their history, classification system, and mechanism of transduction followed by a summary of the existing literature on use of CPPs as gene delivery vectors either in the form of modified viruses, plasmid DNA, small interfering RNA, oligonucleotides, full-length genes, DNA origami or peptide nucleic acids. Keywords: cell penetrating peptides; protein transduction domains; gene therapy; small interfering RNA 1. Introduction The plasma membrane of a cell is essential to its identity and survival, but at the same time presents a barrier to intracellular delivery of potentially diagnostic or therapeutic cargoes.
    [Show full text]
  • 1 Supplemental Material Maresin 1 Activates LGR6 Receptor
    Supplemental Material Maresin 1 Activates LGR6 Receptor Promoting Phagocyte Immunoresolvent Functions Nan Chiang, Stephania Libreros, Paul C. Norris, Xavier de la Rosa, Charles N. Serhan Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. 1 Supplemental Table 1. Screening of orphan GPCRs with MaR1 Vehicle Vehicle MaR1 MaR1 mean RLU > GPCR ID SD % Activity Mean RLU Mean RLU + 2 SD Mean RLU Vehicle mean RLU+2 SD? ADMR 930920 33283 997486.5381 863760 -7% BAI1 172580 18362 209304.1828 176160 2% BAI2 26390 1354 29097.71737 26240 -1% BAI3 18040 758 19555.07976 18460 2% CCRL2 15090 402 15893.6583 13840 -8% CMKLR2 30080 1744 33568.954 28240 -6% DARC 119110 4817 128743.8016 126260 6% EBI2 101200 6004 113207.8197 105640 4% GHSR1B 3940 203 4345.298244 3700 -6% GPR101 41740 1593 44926.97349 41580 0% GPR103 21413 1484 24381.25067 23920 12% NO GPR107 366800 11007 388814.4922 360020 -2% GPR12 77980 1563 81105.4653 76260 -2% GPR123 1485190 46446 1578081.986 1342640 -10% GPR132 860940 17473 895885.901 826560 -4% GPR135 18720 1656 22032.6827 17540 -6% GPR137 40973 2285 45544.0809 39140 -4% GPR139 438280 16736 471751.0542 413120 -6% GPR141 30180 2080 34339.2307 29020 -4% GPR142 105250 12089 129427.069 101020 -4% GPR143 89390 5260 99910.40557 89380 0% GPR146 16860 551 17961.75617 16240 -4% GPR148 6160 484 7128.848113 7520 22% YES GPR149 50140 934 52008.76073 49720 -1% GPR15 10110 1086 12282.67884
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled
    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
    [Show full text]
  • Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
    Review Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms Melpomeni Fani 1,*, Petra Kolenc Peitl 2 and Irina Velikyan 3 1 Division of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, Switzerland; [email protected] 2 Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 3 Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +41-61-556-58-91; Fax: +41-61-265-49-25 Academic Editor: Klaus Kopka Received: 7 February 2017; Accepted: 9 March 2017; Published: 15 March 2017 Abstract: Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon- Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists.
    [Show full text]
  • Download (750Kb)
    The potential role of the novel hypothalamic neuropeptides nesfatin-1, phoenixin, spexin and kisspeptin in the pathogenesis of anxiety and anorexia nervosa. Artur Pałasz a, Małgorzata Janas-Kozik b, Amanda Borrow c, Oscar Arias-Carrión d , John J. Worthington e a Department of Histology, School of Medicine in Katowice, Medical University of Silesia, ul. Medyków 18, 40-752, Katowice, Poland b Department of Psychiatry and Psychotherapy, School of Medicine in Katowice, Medical University of Silesia, ul. Ziolowa 45/47 Katowice, 40-635, Poland c Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, 80523- 161, US d Unidad de Trastornos del Movimiento y Sueño, Hospital General Dr Manuel Gea Gonzalez, Mexico City, Mexico e Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ, UK Abstract Due to the dynamic development of molecular neurobiology and bioinformatic methods several novel brain neuropeptides have been identified and characterized in recent years. Contemporary techniques of selective molecular detection e.g. in situ Real-Time PCR, microdiffusion and some bioinformatics strategies that base on searching for single structural features common to diverse neuropeptides such as hidden Markov model (HMM) have been successfully introduced. A convincing majority of neuropeptides have unique properties as well as a broad spectrum of physiological activity in numerous neuronal pathways including the hypothalamus and limbic system. The newly discovered but uncharacterized regulatory factors nesfatin-1, phoenixin, spexin and kisspeptin have the potential to be unique modulators of stress responses and eating behaviour. Accumulating basic studies revelaed an intriguing role of these neuropeptides in the brain pathways involved in the pathogenesis of anxiety behaviour.
    [Show full text]